11/20/2026 | Press release | Distributed by Public on 11/20/2026 06:01
Today's big story: Will 2027 Be A 2022 Repeat For Stocks?
Vertex Pharmaceuticals (VRTX) stock trades at 33.2 times earnings, against 21.5 for the S&P 500. Buyers paying that premium expect growth to last and need to know where it will come from. Vertex has changed its priorities, however. On its fiscal Q4 2024 call, held on February 10, 2025, management said its work in cystic fibrosis helped drive double-digit revenue growth. Today it emphasizes something else. So what does Vertex talk up now?
Vertex Now Talks Up Five Disease Areas
Vertex held its fiscal Q3 2026 call on November 2, 2026. On it, management described Vertex as a company soon to sell medicines in five disease areas. Vertex completed its purchase of Crinetics Pharmaceuticals, and rare endocrine diseases are now its fourth business. Management plans a fifth in kidney disease.
Cystic fibrosis earned that attention in February 2025. Trikafta, Vertex's main cystic fibrosis drug, made up 92.9% of revenue in fiscal 2024, when its sales grew 14.5%. In fiscal 2025, they grew just 0.7%.
Vertex stock still costs 33.2 times earnings, even as sales of Trikafta, its biggest drug, have nearly stopped growing. If Vertex holds much of your savings, a further slowdown could mean a drop to sit through. When the market has fallen, the Trefis High Quality (HQ) Portfolio has lost about 81 cents for every $1 its benchmark lost, on average. See the HQ record.
Vertex's cystic fibrosis business still holds up, and a newer drug now leads its growth. In Q3 FY2026, cystic fibrosis revenue was $3.3 billion, up 8% from a year earlier, management said. ALYFTREK delivered $706 million of that. Its sales build mostly from patients switching from Trikafta.
How Big Are Vertex's New Medicines Beside Cystic Fibrosis?
The medicines outside cystic fibrosis are growing quickly, but each brought in less than $100 million in Q3 FY2026. Vertex's total revenue grew 12% that quarter, faster than its cystic fibrosis drugs.
CASGEVY, a one-time treatment for sickle cell disease, brought in $99 million in the quarter, which management said was 30% more than in the quarter before. JOURNAVX, a pain medicine, brought in $58 million, up 18% from Q2 FY2026. Its prescriptions rose more than 40% from Q2, reaching over 750 thousand. Sales grew more slowly because of large discounts, a patient support program still in place and a one-time Medicare pricing reset, management said.
Palsonify, a drug for a rare hormone disease called acromegaly, came with Crinetics. Vertex booked $10 million of its sales in September, after the deal closed. For the whole quarter, Palsonify's sales were about $24 million. Povetacicept, a kidney drug for IgA nephropathy, has an FDA decision date of November 30, 2026.
Is Vertex's Move Into New Medicines A Worry?
For a holder, Vertex's move is mildly worrying for now. You pay a premium for a company whose sales still come mostly from cystic fibrosis. Meanwhile, much of the new spending goes to the newer medicines. The biggest parts of the rise in commercial spending in Q3 FY2026 were for povetacicept, JOURNAVX and Palsonify, management said.
Management now expects about $6 billion of operating expenses in 2026 on its adjusted basis, up from its earlier range of $5.65 billion to $5.75 billion. The rise comes from adding Crinetics, it said.
Vertex's P/E is based on twelve months in which it kept 33.1% of revenue as operating profit. In Q3 FY2026 alone, its reported operating margin was 21.8%, against 40.3% a year earlier. In that quarter, cystic fibrosis still brought in far more than any medicine outside it.
So far, cystic fibrosis is still growing, and the newer medicines have yet to show they can matter beside it. Vertex is expected to report in February 2027. That report will show how much CASGEVY, JOURNAVX and Palsonify added in the fourth quarter.
Vertex is still a cystic fibrosis company paying for a bet on new medicines. A bet like that is easier to hold when the rest of your money can keep growing without the same worry.
What If You Could Grow Wealth And Still Sleep At Night?
The Trefis Income Solution pays a dividend yield about 3x the S&P 500's, and it lost less than the S&P 500 in all 9 big selloffs since 2018.
Spot an error or want more like this? Tell us in 10 seconds.